Idecabtagene vicleucel - 2seventy bio
Alternative Names: Abecma; Anti-BCMA CART Cell Therapy - bluebird bio/Celgene; Anti-BCMA CART cells - bluebird bio/Celgene; bb-2121; BMS-986395; ide-celLatest Information Update: 08 Mar 2024
At a glance
- Originator bluebird bio
- Developer 2seventy bio; bluebird bio; Bristol-Myers Squibb; Celgene Corporation
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple myeloma
Most Recent Events
- 05 Feb 2024 Bristol Myers Squibb and 2seventy bio plans to meet Oncologic Drugs Advisory Committee (ODAC) to review sBLA in relapsed or refractory Multiple myeloma
- 26 Jan 2024 The Committee for Medicinal Products for Human Use (CHMP) recommends approval of idecabtagene vicleucel in Multiple myeloma (Second-line therapy or greater) in the European Union
- 20 Dec 2023 Celgene completes the phase II KarMMa trial for Multiple myeloma (Second-line therapy or greater) in USA, Spain, Japan, Belgium, Canada, France, Germany and Italy (IV) (NCT03361748) (EudraCT2017-002245-29)